Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Aug;76(2):865–874. doi: 10.1172/JCI112044

Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.

R J Desnick, L T Ostasiewicz, P A Tishler, P Mustajoki
PMCID: PMC423920  PMID: 3897290

Abstract

To investigate the molecular pathology in acute intermittent porphyria (AIP), the nature of the defective porphobilinogen (PBG)-deaminase was determined in erythrocyte lysates from 165 AIP heterozygotes from 92 unrelated families representing 20 different ethnic or demographic groups. Immunologic and physicokinetic studies revealed the occurrence of four classes of PBG-deaminase mutations. In the majority of families studied, the amount of immunoreactive enzyme protein corresponded to the amount of enzymatic activity, indicating the absence of cross-reacting immunologic material (CRIM) produced by the mutant allele. In 78 of these CRIM-negative families (designated type 1), the affected heterozygotes had half-normal PBG-deaminase activity. In three families (designated CRIM-negative type 2), symptomatic patients had increased urinary excretion of delta-aminolevulinic acid and PBG, and normal levels of erythrocyte PBG-deaminase activity. In contrast, noncatalytic, immunoreactive protein was expressed in heterozygotes from 11 families, about one-eighth of those studied, consistent with mutations in the structural gene for PBG-deaminase. Two types of CRIM-positive mutations were identified: the type 1 mutation had a CRIM/activity ratio of approximately 1.7 and a crossed-immunoelectrophoretic profile in which all the enzyme intermediates were increased, with the B or monopyrrole-enzyme intermediate predominant (B greater than A much greater than C congruent to D greater than E). The mutation altered both the kinetic and stability properties of the noncatalytic immunoreactive enzyme protein. The second CRIM-positive mutation, type 2, had markedly increased levels of noncatalytic immunoreactive protein (CRIM/activity ratio approximately 5.7). Crossed-immunoelectrophoresis revealed markedly increased amounts of the substrate-bound intermediates, B, C, D, and E (B greater than C greater than D greater than E much greater than A). The accumulation of these noncatalytic enzyme intermediates presumably resulted from the enhanced binding and/or defective release of substrate molecules. The conformation of these enzyme-substrate intermediates apparently rendered the complexes more resistant to intraerythrocyte proteolysis. These findings provide evidence for the presence of different allelic mutations in the structural gene for PBG-deaminase and document molecular genetic heterogeneity in AIP.

Full text

PDF
865

Images in this article

868Image
on p.868
869Image
on p.869
869Image
on p.869
869Image
on p.869
870Image
on p.870
870Image
on p.870
870Image
on p.870
870Image
on p.870
870Image
on p.870

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. M., Desnick R. J. Porphobilinogen deaminase: methods and principles of the enzymatic assay. Enzyme. 1982;28(2-3):146–157. doi: 10.1159/000459098. [DOI] [PubMed] [Google Scholar]
  2. Anderson P. M., Desnick R. J. Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes. J Biol Chem. 1979 Aug 10;254(15):6924–6930. [PubMed] [Google Scholar]
  3. Anderson P. M., Desnick R. J. Purification and properties of uroporphyrinogen I synthase from human erythrocytes. Identification of stable enzyme-substrate intermediates. J Biol Chem. 1980 Mar 10;255(5):1993–1999. [PubMed] [Google Scholar]
  4. Anderson P. M., Reddy R. M., Anderson K. E., Desnick R. J. Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect. J Clin Invest. 1981 Jul;68(1):1–12. doi: 10.1172/JCI110223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Astrup E. G. Family studies on the activity of uroporphyrinogen I synthase in diagnosis of acute intermittent porphyria. Clin Sci Mol Med. 1978 Mar;54(3):251–256. doi: 10.1042/cs0540251. [DOI] [PubMed] [Google Scholar]
  6. Battersby A. R., Fookes C. J., Matcham G. W., McDonald E. Biosynthesis of the pigments of life: formation of the macrocycle. Nature. 1980 May 1;285(5759):17–21. doi: 10.1038/285017a0. [DOI] [PubMed] [Google Scholar]
  7. Bonaïti-Pellié C., Phung L., Nordmann Y. Recurrence risk estimation of acute intermittent porphyria based on analysis of porphobilinogen deaminase activity: a Bayesian approach. Am J Med Genet. 1984 Dec;19(4):755–762. doi: 10.1002/ajmg.1320190415. [DOI] [PubMed] [Google Scholar]
  8. Corash L. M., Piomelli S., Chen H. C., Seaman C., Gross E. Separation of erythrocytes according to age on a simplified density gradient. J Lab Clin Med. 1974 Jul;84(1):147–151. [PubMed] [Google Scholar]
  9. Meyer U. A., Strand L. J., Doss M., Rees A. C., Marver H. S. Intermittent acute porphyria--demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med. 1972 Jun 15;286(24):1277–1282. doi: 10.1056/NEJM197206152862401. [DOI] [PubMed] [Google Scholar]
  10. Miyagi K., Cardinal R., Bossenmaier I., Watson C. J. The serum porphobilinogen and hepatic porphobilinogen deaminase in normal and porphyric individuals. J Lab Clin Med. 1971 Nov;78(5):683–695. [PubMed] [Google Scholar]
  11. Mustajoki P. Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria. Ann Intern Med. 1981 Aug;95(2):162–166. doi: 10.7326/0003-4819-95-2-162. [DOI] [PubMed] [Google Scholar]
  12. Orkin S. H., Kazazian H. H., Jr The mutation and polymorphism of the human beta-globin gene and its surrounding DNA. Annu Rev Genet. 1984;18:131–171. doi: 10.1146/annurev.ge.18.120184.001023. [DOI] [PubMed] [Google Scholar]
  13. Russell C. S., Rockwell P. The effects of sulfhydryl reagents on the activity of wheat germ uroporphyrinogen I synthase. FEBS Lett. 1980 Jul 28;116(2):199–202. doi: 10.1016/0014-5793(80)80643-0. [DOI] [PubMed] [Google Scholar]
  14. Sassa S., Zalar G. L., Kappas A. Studies in porphyria. VII. Induction of uroporphyrinogen-I synthase and expression of the gene defect of acute intermittent porphyria in mitogen-stimulated human lymphocytes. J Clin Invest. 1978 Feb;61(2):499–508. doi: 10.1172/JCI108961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Strand L. J., Felsher B. F., Redeker A. G., Marver H. S. Heme biosynthesis in intermittent acute prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity. Proc Natl Acad Sci U S A. 1970 Nov;67(3):1315–1320. doi: 10.1073/pnas.67.3.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Strand L. J., Meyer U. A., Felsher B. F., Redeker A. G., Marver H. S. Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria. J Clin Invest. 1972 Oct;51(10):2530–2536. doi: 10.1172/JCI107068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wang A. L., Arredondo-Vega F. X., Giampietro P. F., Smith M., Anderson W. F., Desnick R. J. Regional gene assignment of human porphobilinogen deaminase and esterase A4 to chromosome 11q23 leads to 11qter. Proc Natl Acad Sci U S A. 1981 Sep;78(9):5734–5738. doi: 10.1073/pnas.78.9.5734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wetterberg L., Floderus Y., Thunell S., Iselius L., Lindsten J. Genetic regulation of the red cell uroporphyrinogen-I-synthetase level in families with acute intermittent porphyria. Clin Genet. 1983 Dec;24(6):403–406. doi: 10.1111/j.1399-0004.1983.tb00094.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES